SEC Company Response from Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771) (HEPA) — Jun 5, 2019
Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771)
Date: June 5, 2019 · CIK: 0001583771 · Accession: 0001104659-19-033936
AI Filing Summary & Sentiment
File numbers found in text: 333-231604
Letter
VIA EDGAR United States Securities Attention: Dorrie Yale Re: ContraVir Pharmaceuticals, Inc. Form S-1 File No. 333-231604
Dear Ms. Yale:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), ContraVir Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Standard Time, on Thursday, June 6, 2019, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
Thank you,
CONTRAVIR PHARMACEUTICALS, INC.
By:
/s/ Robert Foster
Name: Robert Foster
Title: Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm ContraVir Pharmaceuticals, Inc. 399 Thornall Street Edison, NJ 08837 June 5, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale Re: ContraVir Pharmaceuticals, Inc. Form S-1 File No. 333-231604 Dear Ms. Yale: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), ContraVir Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Standard Time, on Thursday, June 6, 2019, or as soon thereafter as possible. Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request. Thank you, CONTRAVIR PHARMACEUTICALS, INC. By: /s/ Robert Foster Name: Robert Foster Title: Chief Executive Officer